Introduction
The generation of new blood vessels, angiogenesis, is a complex multi-step process, which is tightly regulated by many positive and negative factors. 1, 2 Angiogenesis is important for normal embryonic development and for the development of pathologic conditions such as cancer, rheumatoid arthritis, retinopathies, etc. [3] [4] [5] [6] [7] [8] Several lines of direct and indirect evidence indicate that the growth and persistence of solid tumors and their metastasis are angiogenesis dependent. 4, [7] [8] [9] [10] As a strategy for cancer therapy, antiangiogenic therapy attempts to stop new vessels from forming around a tumor and break up the existing network of abnormal capillaries that feeds the cancerous mass. 6, 7, 11, 12 Vasostatin, the N-terminal domain of calreticulin inclusive of amino acids 1-180, is a potent angiogenesis inhibitor, isolated from culture supernatants of an Epstein-Barr virus-immortalized cell line. [13] [14] [15] Purified recombinant vasostatin selectively inhibits basic fibroblast growth factor (bFGF)-induced endothelial cell proliferation in vitro and bFGF-induced angiogenesis in vivo. The recombinant vasostatin also prevented or apparently reduced growth of human Burkitt lymphoma and human colon carcinoma in murine model. 13, 14 Direct intramuscular injection of plasmid DNA is a relatively safe alternative for gene therapy to viral vectors, 16 although the latter is a potential approach in cancer gene therapy studies. 17 It has been reported that the delivery of heterologous genes into skeletal muscle can provide the sustained production of proteins in the circulation. 18 Intramuscular injection of plasmid DNA encoding interferon-␣ or endostatin has showed the inhibition of tumor growth. 18, 19 In the present study, we constructed a plasmid DNA encoding vasostatin and tested whether intramuscular administration of vasostatin gene show antitumor activity in tumor models in mouse. We found that the intramuscular injection of the plasmid DNA encoding vasostatin resulted in sustained expression and the secretion of vasostatin into the blood circulation. Moreover, the injection of plasmid DNA encoding vasostatin showed the apparent inhibition of tumor growth in murine models.
Results

Expression of biologically active vasostatin in vitro
A PCR-amplified cDNA clone encoding the N-domain residues (1~180), vasostatin, was inserted into pSecTag2B. This placed the vasostatin cDNA downstream of the CMV promoter and murine immunoglobulin chain signal peptide and upstream of a c-myc epitope and polyhistidine (His) tag (Figure 1a) . The expression of plasmid DNA by transfected COS cells was confirmed by reverse transcription-PCR (data not shown) and with the use of anti-vasostatin antibodies in Western blotting analysis (Figure 1b) . The biological activity of secreted vasostatin was tested against human umbilical vein endothelial cells (HUVECs primary cells), and a cell line of mouse endothelial cells (SVEC4-10). As a control, the conditioned medium was also tested against non-endothelial cells including mouse NIH/3T3 fibroblast cells, Meth A fibrosarcoma cells and LL/2c Lewis lung carcinoma cells. Conditioned medium from vasostatin-transfected COS cells apparently inhibited HUVEC and SVEC4-10 endothelial cell growth, compared with conditioned medium from the COS cells transfected with control vector or nontransfected cells. In contrast, the treatment had no effect on proliferation of non-endothelial cells (Figure 1c ).
Serum level of vasostatin after intramuscular administration of plasmid pSecTag2B-vaso
Selected doses (12.5 g, 50 g and 100 g) of pSecTag 2B-vaso were administered by intramuscular injection to mice. Mice were treated with twice weekly intramuscular injections of plasmids over a 4-week period or only a single injection. Serum was collected and vasostatin levels were determined by ELISA. Treatment with a single intramuscular injection of 50 g and 100 g plasmid of pSecTag2B-vaso resulted in elevation of vasostatin in serum on days 2, 7 and 14, compared with the controls (Figure 2a) . Moreover, serum levels of vasostatin were also determined using the same schedule of administration that is used for the tumor studies. As shown in Figure 2b , treatment with twice weekly intramuscular injections of pSecTag2B-vaso over a 4-week period showed persistent and more apparently elevated level of vasostatin, compared with a single injection of the plasmids.
Antitumor efficacy of vasostatin gene therapy
The mice were treated starting at day 7 after injection of Meth A fibrosarcoma or LL/2c Lewis lung cancer, when the tumors were palpable. 12.5-to 100-g DNA dose of pSecTag2B-vaso or control plasmid was intramuscularly administered in both tumor models. Treatment with pSecTag2B-vaso twice weekly for 4 weeks resulted in the inhibition of tumor growth (Figure 3a and b), and survival of tumor-bearing mice treated with pSecTag2B-vaso was longer than that of the mice administered with control plasmid (Figure 3c and d). By contrast, treatment with a single injection of pSecTag2B-vaso showed little effect on tumor growth ( Figure 4) . Inhibition of tumor growth by the injection of vasostatin gene was found to be dose-dependent. As shown in Figure 5 , the mice treated by i.m. injection of 50 g or 100 g of vasostatin gene twice weekly for a 4-week per- iod had an apparent reduction in tumor volume, compared with the controls, while the 12.5-g dose had a decreased effect in the inhibition of tumor growth. The treated mice had been investigated in particular for potential side-effects. No adverse consequences were indicated in gross measures such as weight loss, ruffling of fur, life span, behavior and feeding. Furthermore, no pathological changes in liver, lung, kidney, brain, etc, were found by microscopic examination.
Inhibition of angiogenesis
The chicken embryo CAM assay was used to observe in vivo anti-angiogenic activity of pSecTag2B-vaso. Vascularization was apparently inhibited in the treatment with pSecTag2B-vaso, compared with controls (Figure 6a ), while larger, pre-existing vessels were apparently unaffected. A mouse cornea micropocket assay was used to further investigate the effect of vasostatin expression on in vivo angiogenesis. Blood vessel length, clock hours (the proportion of the circumference that is vascularized if the eye is viewed as a clock), and area of neovascularization in micropocket assay were inhibited by 67 ± 6%, 68 ± 9%, and 79 ± 8%, respectively, in the mice treated with pSecTag2B-vaso, compared with those in mice treated with saline alone. Similar results could also be found compared with empty vector.
The effects of vasostatin expression on the tumor vasculature, tumor cell apoptosis and tumor cell proliferation were determined by immunohistochemical staining. Angiogenesis within tumor tissue was estimated counting the number of microvessels on the section staining with an antibody reactive to CD31 (Figure 6b and c) . The treatment with pSecTag2B-vaso resulted in apparent inhibition of angiogenesis in tumors. In addition, the increased apoptotic tumor cells were found within the tumor tissues in mice treated with pSecTag2B-vaso (Figure 6d and e), compared with controls. The percentage of proliferating cells visualized by proliferating cell nuclear antigen (PCNA) staining were 73.4 ± 8.2%, 75.3 ± 6.1% and 76.2 ± 5.7% for treatment with pSecTag2B-vaso, empty vector and saline, respectively. There was no significant difference among the groups (P > 0.05)
Discussion
Several observations have been made in the present study concerning the plasmid encoding vasostatin, antitumor activity and angiogenesis. The i.m. injection of the plasmid DNA encoding vasostatin showed significant antitumor activity. The inhibition of angiogenesis is probably responsible for the antitumor activity. This suggestion is supported by our findings in the present study. In vitro expression of plasmid DNA was confirmed in the transfected cells with the use of anti-vasostatin antibodies in Western blotting analysis and ELISA. The treatment of endothelial cells with the conditioned medium obtained from transfected cells resulted in apparent inhibition of the endothelial cell proliferation. The sustained high level of vasostatin protein in serum could be identified in ELISA. Angiogenesis was apparently inhibited in tumor by immunohistochemical analysis. Angiogenesis was also 
vaso (Vaso), compared with that with empty vector (e-p) or saline alone. (b and c) Inhibition of angiogenesis within tumors by the intramuscular injection of pSecTag2B-vaso. Mice bearing tumors were treated with 100 g pSecTag2B-vaso or empty plasmid or saline alone. Vessel density was determined by counting the number of the microvessels per high-power field in the section with an antibody reactive to CD31, as described in Materials and methods. (d and e) Increase of apoptotic cells within tumor tissues. Apoptotic tumor cells was elevated within tumor tissues obtained from mice treated with pSecTag2B-vaso, compared with controls. Apoptosis was estimated with TUNEL assay, as described in Materials and methods.
inhibited in the chicken embryo CAM assay and mouse corneal assay. The increased apoptotic cells were found within the tumor tissues from the mice treated with plasmid DNA encoding vasostatin. Similar results were also observed with mouse vasostatin gene (data not shown). It has been reported that vasostatin could inhibit endothelial cell proliferation, suppress neovascularization and halt tumor growth. [13] [14] [15] However, the inhibition of angiogenesis and antitumor efficacy were tested with the purified recombinant vasostatin protein. To our knowledge, there are no published reports regarding gene therapy based on vasostatin.
One of the approaches to modulate angiogenesis is the use of agents that specifically inhibit the growth of endothelial cell. 20 Several molecules that exhibit inhibitory effects on endothelial cell growth were recently reported. 9, [21] [22] [23] [24] [25] Treatment with their recombinant proteins, such as angiostatin and endostatin, demonstrated the inhibition of tumor growth. However, there are several limitations to clinical use of the recombinant protein treatment. First, the requirement of prolonged administration increases the treatment cost for patients. 26 Second, it is difficult in the production of recombinant protein due to physical properties and variations in the purification procedure. 17 We found that the case was the same for the production of recombinant vasotatin protein. Third, relatively large quantities present difficult manufacturing and economic considerations. 27 Finally, there exists the challenge of the long-term storage of bioactive protein and the cumbersome daily administration. 28 Thus, an alternative strategy to obviate these problems is the gene therapeutic use to generate protein in vivo, rather than delivering exogenous recombinant protein. 18, 19 Cancer gene therapy using plasmid DNA or viral vector is undergoing evaluation in clinical trial. [29] [30] [31] The choice of vector and delivery strategy is important to ensure the success of cancer gene therapy that promises the efficacy and specificity superior to traditional approaches. 32 Although viral vectors account for the majority of gene delivery approaches because of their high efficiency of transfection, safety is a great concern. By contrast, nonviral vectors may provide a safer alternative. In addition, plasmid DNA vectors are easier to construct, can accept large cDNA inserts, and can be prepared as pure chemical solutions without the risk of contamination with wild-type infectious particles. [33] [34] [35] It has been reported that the delivery of heterologous genes into skeletal muscle can provide the sustained production of proteins in the circulation. 18 Intramuscular injection of plasmid DNA encoding interferon-␣ or endostatin has showed the inhibition of tumor growth. 18, 19 We found in the present study that the inhibition of tumor growth can also be obtained from the vasostatin expressed at a defined distal site by the intramuscular injection of plasmid DNA encoding vasostatin and secreted into the bloodstream. Thus, our results may provide further evidence in support of the view that the utility of a muscledelivered antiangiogenic gene therapy for cancer treatment may be used as a more convenient alternative to the recombinant protein. 18 Taken together, our data in the present study indicate that cancer gene therapy by the intramuscular delivery of plasmid DNA encoding angiogenesis inhibitor, vasostatin, is effective in the inhibition of the systemic angiogenesis and tumor growth in murine models. The findings in the present study also provide further evidence of the anti-tumor effects of the vasostatin, and may be of importance for the further exploration of the application of this molecule in the treatment of cancer.
Materials and methods
Plasmid construction
A cDNA clone encoding vasostatin was isolated by amplifying N-terminal domain (amino acids 1~180) of human calreticulin from human muscle cDNA library (Clontech, Palo Alto, CA, USA) with upstream primer 5'-ATCGAATTCATGGAGCCCGCCGTCTA-3' and downstream primer 5'-CAAAGCTT CTATTCCAA GGAGCCGGAC-3'. The amplified fragment was cloned into pUC18, and then subcloned into expression vector plasmid pSecTag2B (Invitrogen, La Jolla, CA, USA), which contains a cytomegalovirus promotor. Vasostatin inserted into pSecTag2B was named pSecTag2B-vaso. As a control, pure plasmid was used as an empty vector (ep). The full-length sequence of vasostatin was confirmed by dideoxy sequence to be identical to that in Genebank (GI:5921996) and those reported. [13] [14] [15] The expression plasmid pSecTag2B-vaso and the empty vector pSecTag2B were purified by using two rounds of passage over EndoFree columns (Qiagen, Chatsworth, CA), as reported previously by us 36 and others. 37 Western blot analysis Western blot analysis was performed as described. 18 Briefly, COS cells were plated in six-well plates at 2 × 10 5 cells/well, and transfected with 2 g of plasmid and 4 g lipofectin (Life Technologies, Grand Island, NY, USA) in serum-free DMEM following the manufacturer's instructions. After addition of lipofectin reagent-DNA complex, the cells were incubated at 37°C for 12 h. The lipofectin reagent-DNA complex-containing medium was then replaced with normal growth medium, and the cells were further incubated at 37°C for 60 h before the conditioned medium was collected. Ten microliters of the conditioned media were mixed with 2 × sodium dodecyl sulfate sample buffer and were separated on a 12% SDS-PAGE gel. Gels were electroblotted with Sartoblot on to a poly(vinylidene difluoride) membrane. The membrane blots were blocked at 4°C in 5% nonfat dry milk, washed, and probed with goat-anti-N-terminal calreticulin (vasostatin) antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1/200. Blots were then washed and incubated with a biotinylated secondary antibody (biotinylated rabbit anti-goat IgG), followed by transfer to Vectastain ABC (Vector Laboratories, Burlingame, CA, USA).
36
In vitro biological assay for vasostatin Biological activity of vasostatin was determined using conditioned medium from transfected cells in endothelial cell proliferation assay. 36, 38 Briefly, 3000 endothelial cells (HUVECs and SVEC4-10), non-endothelial cells (NIH/3T3 fibroblast and T/G HA-VSMCs) or tumor cells (Meth A and LL/2c) were plated on to 96-well culture plates in triplicate and incubated (37°C, 5% CO 2 ) for 24 h in 100 l medium containing bFGF. The medium was replaced with 20 or 40 l of vasostatin-containing supernatant from transfected COS cells mentioned above or control cells. After 20 min of incubation, 80 or 60 l of medium were added. After 72 h, the cell number was determined by a trypan blue dye exclusion test, and the percentage inhibition was calculated by the following formula as described: inhibition % = [(NϪN T )/(NϪNo)] × 100, where N is the number of untreated cells cultured for n days, No is the cell number on day 0, and N T is the number of treated cells cultured for n days. 3, 36, 38 
ELISA determination of vasostatin expression
The level of vasostatin in serum after intramuscular administration of vasostatin expression plasmid was Gene Therapy assayed by ELISA using a protocol similar to one described previously. 18 Ninety-six-well microtiter plates (Falcon) were coated with goat-anti-vasostatin (N-terminal calreticulin) antibody (Santa Cruz Biotechnology) in 50 mM carbonate buffer (1/200 dilution) at 4°C overnight and blocked with 150 l/well of 2% bovine serum albumin in phosphate-buffered saline (PBS) at room temperature for 4 h. Sera diluted 1/5 (100 l/well) was added and incubated for 1 h at 37°C. Mouse monoclonal anti-c-myc epitope (Invitrogen) diluted 1/1000 in HBSTween-BSA buffer (23.8 M HEPES, 5.84 M NaCl, 1.0%BSA, 0.1% Tween 20; pH7.2) was added (100 l/well) and incubated for 1 h at 37°C. Alkaline phosphatase-conjugated rabbit anti-mouse IgG (Sigma, St Louis, MO, USA) diluted 1/3000 in HBS-Tween-BSA buffer was added (100 l/well) and incubated for 1 h at 37°C. After washing four times in washing buffer, phosphatase substrate CP-nitrophenyl phosphate (Sigma) was added for 30 min, and absorbance was measured at 405 nm with an ELISA reader (BioRad, Hercules, CA, USA). Serial dilutions recombinant vasostatin were used as a standard. The concentration of vasostatin from cell culture was also assayed as described above. Assays were done in triplicate. The recombinant vasostatin was expressed, refolded, and purified from Escherichia coli, as detailed previously.
13,14
Choriallantoic membrance (CAM) assay Chicken CAM assay were performed as described by us 39 and others. 40, 41 Briefly, fertilized White Leghorn chicken eggs were incubated for 3 days at 37°C and 60% humidity. A square window was opened in the shell and 2 to 3 ml of albumen was removed to allow detachment of the developing CAM. Filter disks of No. 1 filter paper (Whatman, Clifton, NJ, USA) were soaked in 3 mg/ml cortisone acetate (Sigma) in a solution of 95% ethanol and water and subsequently air-dried under sterile conditions. Sterile filter disks adsorbed with bFGF dissolved in PBS at 150 ng/ml were placed on growing CAMs. At 24 h, 20 to 200 g in 50 l of pSecTag2B-vaso or vector plasmid dissolved in saline, or saline alone was added to CAMs topically. The windows were sealed with tape and the eggs were incubated for 3 or 5 days. The CAMs were photographed by a stereomicroscope and vascularization was estimated.
Corneal micropocket assay
Mouse corneal assay was performed as described. 3, 18, 36 Five mice in each group were anesthetized. Corneal micropockets were created with a cataract knife. HydronSucralfate pellets (Hydron, Interferon Sciences, New Brunswick, NJ, USA; Aluminum sucrose sulfate, Sigma) containing bFGF at 1 g/ml were formulated and implanted into the cornea pockets of mice 0.3 to 0.5 mm from the limbus. The pSecTag2B-vaso, empty vector or saline was administered intramuscularly 1 day before implantation of hydron pellet. The corneas of mice were examined daily. 42 
Murine tumor models and treatment
Animal studies were performed in accordance with institutional guidelines concerning animal use and care. Meth A fibrosarcoma and LL/2c Lewis Lung carcinoma models were established in BALB/c and C57BL/6 mice, respectively. Mice bearing tumor were injected intramus-cularly with different doses of pSecTag2B-vaso or control vector in 100 l of saline. Additional control animals were injected with 100 l normal saline. Mice were treated with twice weekly over a 4-week period as described, 19 or with only a single injection, after tumors had been established.
Histological analysis
For the observations of potential side-effects in the treated mice, the tissues of heart, liver, spleen, lung, kidney, brain, etc, were fixed in 10% neutral buffered formalin solution and embedded in paraffin. Sections 3-5-m were stained with hematoxylin and eosin (HE). 43 Immunohistochemistry was done as described. 3, 18 Briefly, for CD31 immunostaining, 4% paraformaldehyde-fixed, paraffin-embedded sections from tumor tissues were incubated with a monoclonal rat anti-mouse CD31 at a 1:400 dilution (Pharmingen, San Diego, CA, USA) at 4°C overnight. Following washes in PBS, the secondary antibody, biotinylated rabbit anti-rat antibody at a 1:100 dilution (Dako, Carpinteria, CA, USA) was added. The sections were then stained with streptavidin biotin reagents (Dako LSAB kit, peroxidase). Vessel density was determined by counting the number of microvessels per high-power field in the section with an antibody reactive to CD31, as described. 3, 9, 26 Immunostaining for PCNA was performed as previously described. 44 Polyclonal rabbit anti-mouse PCNA (Santa Cruz) was used at a dilution of 1:200. TUNEL staining was performed using an in situ apoptotic cell detection kit (Boehringer Mannheim) following the manufacturer's protocol. It is based on the enzymatic addition of digoxigenin-nucleotide to the nicked DNA by terminal deoxynucleotidyl transferase. Sections in HE staining and immunohistochemical staining were observed by two pathologists in a blinded manner.
